Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 6, 2008, Pages 749-757

  Ansari, A ^a   Aslam, Z ^a   De Sica, A ^a   Smith, M ^a   Gilshenan, K ^b   Fairbanks, L ^a   Marinaki, A ^a   Sanderson, J ^a   Duley, J ^c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b MATER HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6 THIOURIC ACID; ALLOPURINOL; AZATHIOPRINE; MERCAPTOPURINE; MESALAZINE; THIOPURINE METHYLTRANSFERASE; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DEMOGRAPHY; DISEASE ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; DRUG WITHDRAWAL; ENZYME ACTIVITY; FIRST PASS EFFECT; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TOXIC HEPATITIS;

6-MERCAPTOPURINE; ADULT; BIOLOGICAL AVAILABILITY; CASE-CONTROL STUDIES; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINE, SMALL; METHYLTRANSFERASES; URIC ACID; XANTHINE OXIDASE;

EID: 49849105122     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03768.x     Document Type: Article

References (42)

1. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002 16 : 1743 50.
2. Arenas M, Marinaki A, Ansari A, Sanderson J. Typing TPMT and ITPase to detect azathioprine toxicity. Personalized Medicine 2006 3 : 45 59.
3. Sanderson J, Ansari A, Marinaki T, Duley J. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem 2004 41 : 294 302.
4. Bronk JR, Lister N, Shaw MI. Transport and metabolism of 6-thioguanine and 6-mercaptopurine in mouse small intestine. Clin Sci (Lond) 1988 74 : 629 38.
5. Stow RA, Bronk JR. Purine nucleoside transport and metabolism in isolated rat jejunum. J Physiol 1993 468 : 311 24.
6. Huh K, Yamamoto I, Gohda E, Iwata H. Tissue distribution and characteristics of xanthine oxidase and allopurinol oxidizing enzyme. Jpn J Pharmacol 1976 26 : 719 24.
7. Kurowski V, Iven H. Plasma concentrations and organ distribution of thiopurines after oral application of azathioprine in mice. Cancer Chemother Pharmacol 1991 28 : 7 14.
8. Harkness RA, McCreanor GM, Simpson D, MacFadyen IR. Pregnancy in and incidence of xanthine oxidase deficiency. J Inherit Metab Dis 1986 9 : 407 8.
9. Simmonds HA, Reiter S, Nishino T Hereditary xanthinuria. In : Scriver CR, Beaudet AL, Sly WS, Valle D eds. The Metabolic Basis of Inherited Disease, 7th ed. NY : McGraw-Hill, 1995 : 1781 97.
10. Kashuba AD, Bertino JS Jr., Rocci ML Jr., Kulawy RW, Beck DJ, Nafziger AN. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 1998 64 : 269 77.
11. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992 52 : 643 58.
12. Zimm S, Collins JM, Riccardi R, et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 1983 308 : 1005 9.
13. Serre-Debeauvais F, Bayle F, Amirou M, et al. Hematotoxicity caused by azathioprine genetically determined and aggravated by xanthine oxidase deficiency in a patient following renal transplantation. Presse Med 1995 24 : 987 8.
14. Lysaa RA, Giverhaug T, Wold HL, Aarbakke J. Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol 1996 49 : 393 6.
15. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995 39 : 456 9.
16. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001 49 : 656 64.
17. de Boer NK, Wong DR, Jharap B, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007 102 : 2747 53.
18. Gilissen LP, Bierau J, Derijks LJ, et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther 2005 22 : 605 11.
19. Hande S, Wilson-Rich N, Bousvaros A, et al. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 2006 12 : 251 7.
20. EGoRT E. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.9.2. Haematological complications. Leukopenia. Nephrol Dial Transplant 2002 17 (Suppl. 4 49.
21. Chocair P, Duley J, Simmonds HA, et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 1993 342 : 83 4.
22. Chrzanowska M, Krzymanski M. Determination of 6-thioguanine and 6-methylmercaptopurine metabolites in renal transplantation recipients and patients with glomerulonephritis treated with azathioprine. Ther Drug Monit 1999 21 : 231 7.
23. Sparrow M, Hande S, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005 22 : 441 6.
24. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007 5 : 209 14.
25. Boda M, Nemeth I, Boda D. The caffeine metabolic ratio as an index of xanthine oxidase activity in clinically active and silent celiac patients. J Pediatr Gastroenterol Nutr 1999 29 : 546 50.
26. Anup R, Susama P, Balasubramanian KA. Role of xanthine oxidase in small bowel mucosal dysfunction after surgical stress. Br J Surg 2000 87 : 1094 101.
27. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976 70 : 439 44.
28. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002 122 : 512 30.
29. Simmonds HA, Duley JA, Davies PM. Analysis of purines and pyrimidines in blood, urine and other physiological fluids. In : Hommes FA, ed. Techniques in Diagnostic Human Biochem Genetics. NY : Wiley-Liss, 1990 : 397 424.
30. Jackson PJ. Determination of 6-thiouric acid in human urine. Clin Biochem 1983 16 : 285 6.
31. Elion GB. Significance of azathioprine metabolites. Proc R Soc Med 1972 65 : 257 60.
32. Coulthard SA, Hogarth LA, Little M, et al. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol Pharmacol 2002 62 : 102 9.
33. Elion GB. The purine path to chemotherapy. Science 1989 244 : 41 7.
34. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004 53 (Suppl. 5 V1 16.
35. Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999 117 : 527 35.
36. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004 350 : 1093 103.
37. Krenitsky TA, Neil SM, Elion GB, Hitchings GH. A comparison of the specificities of xanthine oxidase and aldehyde oxidase. Arch Biochem Biophys 1972 150 : 585 99.
38. Arndt CA, Balis FM, McCully CL, et al. Bioavailability of low-dose vs high-dose 6-mercaptopurine. Clin Pharmacol Ther 1988 43 : 588 91.
39. Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 2007 26 : 987 1003.
40. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007 46 : 187 208.
41. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002 122 : 904 15.
42. Keuzenkamp-Jansen CW, DeAbreu RA, Bokkerink JP, Lambooy MA, Trijbels JM. Metabolism of intravenously administered high-dose 6-mercaptopurine with and without allopurinol treatment in patients with non-Hodgkin lymphoma. J Pediatr Hematol Oncol 1996 18 : 145 50.